CClinicalTrials.gg
Sign In
Status unknownNCT01745328Updated Dec 10, 2012

Treatment of Recurrent Urinary Tract Infection (RUTI) by Traditional Chinese Medicine

An interventional study of LVX-AMX and TCM in Recurrent Urinary Tract Infection, sponsored by Beijing Institute of Disease Control and Prevention. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-12-10.

Sponsored by Beijing Institute of Disease Control and Prevention · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2012), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Traditional Chinese Medicine (TCM) could be used to treat Recurrent urinary tract infection (RUTI).

Read the detailed description

Antibiotics and TCM are used to treat RUTI to evaluate treatment efficiencies.

02

Conditions studied

  • Recurrent Urinary Tract Infection

Keywords

  • recurrent urinary tract infection
  • antibiotics
  • traditional chinese medicine
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's planned enrollment of 150 is above the median of 120 across 4,201 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

This is the only study on the registry with Beijing Institute of Disease Control and Prevention as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • uncomplicated RUTI

Exclusion criteria

Exclusion Criteria:

  • complicated RUTI
  • other disease with urinary tract
  • infection by pathogens other than bacteria
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    LVX-AMX

    subject is treated with LAV-AMX, then followed by placebo.

    Drug: LVX-AMX

  • Active comparator
    TCM treatment

    subject is treated with TCM

    Drug: TCM

Interventions

  • DrugLVX-AMX

    Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.

    Also known as: Levofloxacin, 200mg bid, Amoxicillin, 500mg tid

  • DrugTCM

    Subject is treated with TCM for 4 weeks.

    Also known as: TCM formula consisted of 10 herbals

  • DrugLVX-AMX

    treatment with placebo from 2 to 4 weeks.

    Also known as: placebo from 2 to 4 weeks.

06

What researchers measure

Primary outcomes

  1. Recovery of recurrent urinary tract infection

    Patients are checked at 4 weeks at the end of the treatment to confirm recovery of RUTI.

    Time frame: 4 weeks after study drug start

Secondary outcomes

  1. Urinary albumin

    Urinary albumin is checked in patient urine.

    Time frame: 4 weeks after drug start

  2. WBC conversion

    Check the WBC count in patient urine.

    Time frame: 4 weeks after drug start

  3. Urination frequency

    Checked for urination frequency at 4 weeks after drug start.

    Time frame: 4 weeks after drug start

  4. Recurrence

    Patients are checked for recurrence rate at 6 months after drug start by telephone interview.

    Time frame: 6 months after drug start

  5. urgency

    Check urgency 4 weeks after drug start

    Time frame: 4 weeks after drug start

07

Study locations

1 of 1 sites recruiting
  • Wangjing Hospital
    Beijing, Beijing 100020, China
    Recruiting
08

References and documents

Publications

  • Liu SW, Guo J, Wu WK, Chen ZL, Zhang N. Treatment of Uncomplicated Recurrent Urinary Tract Infection with Chinese Medicine Formula: A Randomized Controlled Trial. Chin J Integr Med. 2019 Jan;25(1):16-22. doi: 10.1007/s11655-017-2960-4. Epub 2017 Jul 25. PubMed 28741061 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01745328
Lead sponsor
Beijing Institute of Disease Control and Prevention
Responsible party
Sponsor
First posted
Dec 10, 2012
Start date
Jan 2009
Primary completion
Mar 2013 (estimated)
Completion
Jul 2013 (estimated)
Last update
Dec 10, 2012

Study contacts

Shiwei Liu, Dr
Contact
liushiwei1977@yeah.net
86-10-84739029
Zeliang Chen, Dr
principal investigator · Insititute of Disease Control and Prevention

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Infections→

Start the discussion